Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Shay Yeganeh"'
Autor:
Zufit Hexner‐Erlichman, Joanne Yacobovich, Philippe Trougouboff, Moran Avraham‐Kelbert, Harel Eitam, Ronen Spiegel, Shay Yeganeh, Carina Levin
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 304-308 (2020)
Abstract Autoimmune myelofibrosis (AIMF) is an uncommon cause of myelofibrosis associated with favorable outcome. Primary AIMF, AIMF without a known systemic autoimmune disorder, has been described in adults, but never in children. Here, we present,
Externí odkaz:
https://doaj.org/article/5b8248cb7e8b47b9b4a21f451d5ab2d7
Autor:
Tsila Zuckerman, Ron Ram, Luiza Akria, Maya Koren-Michowitz, Ron Hoffman, Israel Henig, Noa Lavi, Yishai Ofran, Netanel A. Horowitz, Olga Nudelman, Sigal Tavor, Shay Yeganeh, Stela Gengrinovitch, Liat Flaishon, Shoshi Tessler, Ruth Ben Yakar, Jacob M. Rowe
Publikováno v:
Blood Advances, Vol 3, Iss 22, Pp 3740-3749 (2019)
Abstract: High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to increased toxicity. BST-236 (INN aspacytarabine) is a novel cytarabine prodrug designed t
Externí odkaz:
https://doaj.org/article/196dcbc92ead43e590e0016ecd87a86a
Autor:
Chezi Ganzel, Svetlana Trestman, Shai Levi, Moshe E. Gatt, Noa Lavi, Iuliana Vaxman, Ory Rouvio, Hila Magen, Eyal Lebel, Netanel A. Horowitz, Merav Leiba, Tamar Tadmor, Katrin Herzog Tzarfati, Celia Surio, Shay Yeganeh, Nagib Dally, Irit Avivi, Yael C. Cohen
Publikováno v:
Leukemialymphoma.
Solitary plasmacytoma (SP) is a rare plasma cell dyscrasia. In this retrospective multicenter study, 68 SP patients were included. Compared to solitary extramedullary plasmacytoma (SEP), patients with solitary bone plasmacytoma (SBP) were younger (57
Autor:
Gilad Itchaki, Ohad Benjamini, Mor Levi, Anatoly Nemets, Shay Yeganeh, Mahdi Assaly, Anna Gourevitch, Revital Saban, Moshe E Gatt, Pia Raanani, Iuliana Vaxman
Publikováno v:
Blood. 140:11981-11982
Autor:
Harel Eitam, Moran Avraham-Kelbert, Ronen Spiegel, Joanne Yacobovich, Carina Levin, Philippe Trougouboff, Zufit Hexner-Erlichman, Shay Yeganeh
Publikováno v:
eJHaem. 1:304-308
Autor:
Moshe Mittelman, Yehonatan Sherf, Daniela Goldstein, Tamar Tadmor, Tamar Berger, Reut Harel, Orit Sofer, Eran Zimran, Nagib Dally, Jabour Halloun, Merav Leiba, Gilad Itchaki, Andrei Braester, Maya Koren-Michowitz, Martin Ellis, Nadav Sarid, Shlomzion Aumann, Lev Shvidel, Tsila Zuckerman, Itai Levi, Avital Lavi, Ofer Shpilberg, Ariel Aviv, Noa Lavi, Sharon Ben Barouch, Pia Raanani, Ilana Levy, Katrin Herzog Tzarfati, Sigal Grisariu, Shay Yeganeh, Celia Suriu, Osnat Dolberg Jarchowsky
Publikováno v:
Leukemialymphoma. 62(14)
This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory dat
Autor:
Maya Koren-Michowitz, Sharon Gino-Moor, Miri Zektser, Jacob M. Rowe, Galit Peretz, Shay Yeganeh, Chezi Ganzel, Ronit Yerushalmi, Alexander Gural, Vladimir Vainstein, Ivetta Danylesko, Boaz Nachmias, Yosef Cohen, Arie Apel, Yishai Ofran, Yakir Moshe, Ron Ram, Oren Pasvolsky, Ofir Wolach
Publikováno v:
Leukemialymphoma. 61(9)
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016-2019, forty patients were identified. Median age was 67 years (21-82), 60% males, median of
Autor:
Sigal Tavor, Tsila Zuckerman, Israel Henig, Shoshi Tessler, Jacob M. Rowe, Ron Ram, Maya Koren-Michowitz, Stela Gengrinovitch, Luiza Akria, Shay Yeganeh, Liat Flaishon, Noa Lavi, Ruth Ben Yakar, Olga Nudelman, Ron Hoffman, Yishai Ofran, Netanel A. Horowitz
High-dose cytarabine is the backbone of acute myeloid leukemia (AML) treatment. Nevertheless, its use in older patients is considerably limited due to increased toxicity. BST-236 (INN aspacytarabine) is a novel cytarabine prodrug designed to deliver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213bc297a01c1eda08aaf07df1375517
https://europepmc.org/articles/PMC6880904/
https://europepmc.org/articles/PMC6880904/
Autor:
Merav Leiba, Irit Avivi, Hila Magen, Shay Yeganeh, Svetlana Trestman, Chezi Ganzel, Cohen Yael, Celia Surio, Moshe E. Gatt, Tamar Tadmor, Shai Levi, Netanel A. Horowitz, Nagib Deli, Iuliana Vaxman, Katrin Herzog Tzarfati, Ory Rouvio, Noa Lavi
Publikováno v:
Blood. 134:3180-3180
Background: Solitary plasmacytoma (SPC) is a rare plasma cells disorder, which may present as a single bone lesion or an extramedullary plasmacytoma. High dose radiotherapy may be curative, yet most patients eventually develop Multiple Myeloma (MM).
Autor:
Alexander Gural, Ronit Yerushalmi, Jacob M. Rowe, Maya Koren-Michowitz, Oren Pasvolsky, Vladimir Vainstein, Shay Yeganeh, Chezi Ganzel, Boaz Nachmias, Miri Zektzer, Yakir Moshe, Sharon Gino-Moor, Yishai Ofran, Arie Apel, Yoseph Cohen, Ron Ram, Ofir Wolach, Ivetta Danylesko, Galit Perets
Publikováno v:
Blood. 134:5091-5091
Introduction: On November 2018 the FDA approved the treatment of venetoclax together with hypomethylating agent (HMA) or low dose cytarabine (LDAC) for newly diagnosed AML patients who cannot tolerate intensive chemotherapy. There is limited data reg